Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?

Alex Renner; Mauricio Burotto; Jose Miguel Valdes; Juan Carlos Roman; Annerleim Walton-Diaz

doi:10.1177/17562872211029779

Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?

Alex Renner, Mauricio Burotto, Jose Miguel Valdes, Juan Carlos Roman, Annerleim Walton-Diaz^*

^*Corresponding author for this work

Clínica Universidad de los Andes

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

Immunotherapy, in the form of immune checkpoint inhibitors (ICI), has shown activity in metastatic urothelial bladder carcinoma, resulting in the approval of several ICI agents in the first- and second-line settings. This has led to an increased interest in studying their efficacy in the neoadjuvant setting for muscle invasive disease – an area of significant unmet need. This non-systematic review will look at the evidence supporting the use of ICI in the neoadjuvant setting for this tumor, results of early-phase studies, ongoing trials, and possible future applications for these drugs.

Original language	English
Pages (from-to)	17562872211029779
Journal	Therapeutic Advances in Urology
Volume	13
DOIs	https://doi.org/10.1177/17562872211029779
State	Published - 23 Jul 2021

Bibliographical note

Publisher Copyright:
© The Author(s), 2021.

Keywords

bladder cancer
immune checkpoint inhibitor
immunotherapy
muscle invasive
neoadjuvant

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/17562872211029779

Cite this

@article{264fa799d54e40b695737a784046545b,

title = "Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?",

abstract = "Immunotherapy, in the form of immune checkpoint inhibitors (ICI), has shown activity in metastatic urothelial bladder carcinoma, resulting in the approval of several ICI agents in the first- and second-line settings. This has led to an increased interest in studying their efficacy in the neoadjuvant setting for muscle invasive disease – an area of significant unmet need. This non-systematic review will look at the evidence supporting the use of ICI in the neoadjuvant setting for this tumor, results of early-phase studies, ongoing trials, and possible future applications for these drugs.",

keywords = "bladder cancer, immune checkpoint inhibitor, immunotherapy, muscle invasive, neoadjuvant",

author = "Alex Renner and Mauricio Burotto and Valdes, {Jose Miguel} and Roman, {Juan Carlos} and Annerleim Walton-Diaz",

note = "Publisher Copyright: {\textcopyright} The Author(s), 2021.",

year = "2021",

month = jul,

day = "23",

doi = "10.1177/17562872211029779",

language = "English",

volume = "13",

pages = "17562872211029779",

journal = "Therapeutic Advances in Urology",

issn = "1756-2872",

publisher = "SAGE Publications Inc.",

}

TY - JOUR

T1 - Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma

T2 - will it change current standards?

AU - Renner, Alex

AU - Burotto, Mauricio

AU - Valdes, Jose Miguel

AU - Roman, Juan Carlos

AU - Walton-Diaz, Annerleim

N1 - Publisher Copyright: © The Author(s), 2021.

PY - 2021/7/23

Y1 - 2021/7/23

N2 - Immunotherapy, in the form of immune checkpoint inhibitors (ICI), has shown activity in metastatic urothelial bladder carcinoma, resulting in the approval of several ICI agents in the first- and second-line settings. This has led to an increased interest in studying their efficacy in the neoadjuvant setting for muscle invasive disease – an area of significant unmet need. This non-systematic review will look at the evidence supporting the use of ICI in the neoadjuvant setting for this tumor, results of early-phase studies, ongoing trials, and possible future applications for these drugs.

AB - Immunotherapy, in the form of immune checkpoint inhibitors (ICI), has shown activity in metastatic urothelial bladder carcinoma, resulting in the approval of several ICI agents in the first- and second-line settings. This has led to an increased interest in studying their efficacy in the neoadjuvant setting for muscle invasive disease – an area of significant unmet need. This non-systematic review will look at the evidence supporting the use of ICI in the neoadjuvant setting for this tumor, results of early-phase studies, ongoing trials, and possible future applications for these drugs.

KW - bladder cancer

KW - immune checkpoint inhibitor

KW - immunotherapy

KW - muscle invasive

KW - neoadjuvant

UR - http://www.scopus.com/inward/record.url?scp=85109410824&partnerID=8YFLogxK

U2 - 10.1177/17562872211029779

DO - 10.1177/17562872211029779

M3 - Article

C2 - 34290827

AN - SCOPUS:85109410824

SN - 1756-2872

VL - 13

SP - 17562872211029779

JO - Therapeutic Advances in Urology

JF - Therapeutic Advances in Urology

ER -

Neoadjuvant immunotherapy for muscle invasive urothelial bladder carcinoma: will it change current standards?

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this